BMP2 and plasma cell myeloma: Furthermore, ACVR1/ALK2 is -in contrast to BMPRIA and -IB- ubiquitously expressed in myeloma cells, which potentially renders BMP6 a more versatile Activin A antagonist than BMP2 [49].